Patent EA-000576-B1 (EA)
Title: Method of binding and inactivation of viruses
IPC: A01N63/60
Filed: 1996-03-08
Abstract: 1. A method of binding and inactivation of viruses in an animal comprising contacting a mucosal surface of the host with an amount of transformed bacteria expressing a structure on its surface, binding the virus sufficient protecting an animal from a viral infection comprising contacting a mucosal surface of the host with an amount of transformed bacteria sufficient to colonize the mucosal surface and to protect the animal from viral infection, said bacteria having been transformed with genetic material so as to confer upon the bacteria the capacity to bind the virus. 2. A method of Claim 1 where the transformed bacteria expresses a polypeptide on its surface which serves as the host receptor for the virus. 3. A method of Claim 2 where the bacteria are transformed with genetic material which induces surface expression of a protein with comprising an ICAM-1 domain, where the virus is a human rhinovirus, and the host is human. 4. A method of Claim 2 where the bacteria are transformed with genetic material which induces surface expression of a protein with a CD4 receptor, the virus is a human immunodeficiency virus, and the host is human. 5. A method of Claim 2 where the bacteria are transformed with genetic material which induces surface expression of a protein with a poliovirus receptor, the virus is a poliovirus, and the host is human. 6. A method of Claim 2 where the bacteria are transformed with genetic material which induces surface expression of a protein with a human complement receptor 2, the virus is an "epstein-barr" virus, and the host is human. 7. A method of Claim 1 where the transformed bacteria expresses on its surface an antibody fragment against a conserved determinant on the virus. 8. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a monomorphic determinant of the human HLA DR molecule, the virus is a human immunodeficiency virus, and the host is human. 9. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the rotavirus coat protein, the virus is a rotavirus, and the host is human. 10. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the herpes simplex virus coat protein, the virus is a herpes simplex virus, and the host is human. 11. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the human papilloma virus coat protein, the virus is a human papilloma virus, and the host is human. 12. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the adenovirus coat protein, the virus is an adenovirus and the host is human. 13. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the respiratory syncytia virus coat protein, the virus is a respiratory syncytia virus, and the host is human. 14. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the corona virus coat protein, the virus is a corona virus, and the host is human. 15. A method of Claim 7 where the bacteria are transformed with genetic material which induces surface expression of an antibody fragment against a conserved determinant on the capsids of a virus selected from the group consisting of: cytomegalovirus, coxsackievirus. echovirus, hepatitis A virus and parainfluenza virus. 16. A method of Claim 1 where the bacteria are transformed with genetic material which causes the addition of sialic acid residues onto its normal surface proteins, the virus is an influenza virus, and the host is human. 17. A method of Claim 16 wherein the transformed bacteria fuses with bound viral particles through a fusogenic domain engineered into the virus-binding polypeptide. 18. A method of Claims 1-17 wherein the transformed bacteria is conferred enhanced ability to adhere to a host mucosal surface through a domain in the heterologous protein which binds to a determinant on a selected mucosal surface. 19. A method of Claim 1 where the mucosal surface is the nasopharynx, oropharynx, esophagus, small intestines, large intestines, rectum, vagina, or penis. 20. A method of Claim 1-19 where transformed bacteria are applied to a mucosal surface through the use of a liquid solution, foam, suppository, sponge, or capsule. 21. A method of binding and inactivation of viruses protecting a woman from an infection transmitted through vaginal intercourse by the application of transformed bacteria into the vaginal vault at the time of intercourse that binds and inactivates an infectious agent. 22.A method of Claim 21 where the virus is a human papilloma virus, or a herpes simplex virus. 23. A method of Claim 22 where the transformed bacteria are administered in the form of a vaginal foam or sponge. 24. A method of Claim 23 where the transformed bacteria may be administered in conjunction with other agents such as nonbacteriocidal spermicides. 25. A method of binding and inactivation of viruses transformed from an infected individual comprising contacting a mucosal surface of the host with an amount of transformed bacteria expressing a structure on its surface, binding the virus.